论文部分内容阅读
目的探讨采用苯甲酸雌二醇治疗卵巢早衰患者时对患者骨代谢以及骨密度的影响。方法选取2014年2月-2015年2月在医院进行治疗的卵巢早衰患者100例作为治疗组,按照随机数字表方法分为治疗1组和治疗2组各50例;选取同期在医院进行体检的健康女性100例作为对照组。治疗1组的患者采用苯甲酸雌二醇进行治疗,治疗2组的患者采用雌激素联合醋酸甲羟孕酮序贯治疗。比较各组患者治疗前、后的骨代谢以及骨密度相关指标(包括腰椎骨密度、股骨颈骨密度、25-羟基维生素D3、骨钙素),比较各组患者治疗前、后的临床相关指标(包括雌二醇、血糖、三酰甘油、总胆固醇)。结果治疗1组患者经治疗后腰椎骨密度、股骨颈骨密度显著低于对照组,差异有统计学意义(P<0.05);治疗2组患者经治疗后腰椎骨密度、股骨颈骨密度、25-羟基维生素D3水平显著低于对照组,差异有统计学意义(P<0.05);治疗后治疗1组患者的腰椎骨密度、股骨颈骨密度、25-羟基维生素D3水平显著高于治疗2组患者,骨钙素水平显著低于治疗2组患者,雌二醇水平显著高于治疗2组患者,胆固醇水平显著低于治疗2组患者,差异均有统计学意义(P<0.05)。结论对卵巢早衰的患者采用苯甲酸雌二醇进行治疗,能够很好地促进患者骨密度的增加,降低骨质疏松的发生率,并且不会造成严重的不良反应。
Objective To investigate the effects of estradiol benzoate on bone metabolism and bone mineral density in patients with premature ovarian failure. Methods 100 cases of premature ovarian failure patients who were treated in hospital from February 2014 to February 2015 were selected as treatment group and divided into treatment group 1 and treatment group 50 according to random number table method. 100 healthy women as control group. Patients in treatment group 1 were treated with estradiol benzoate, and patients in two groups were treated sequentially with estrogen plus medroxyprogesterone acetate. The bone metabolism and BMD (including lumbar spine BMD, femoral neck BMD, 25-hydroxyvitamin D3 and osteocalcin) before and after treatment were compared between the two groups before and after treatment to compare the clinical indicators (Including estradiol, blood glucose, triglycerides, total cholesterol). Results After treatment, the lumbar BMD and the femoral neck BMD in the treatment group 1 were significantly lower than those in the control group (P <0.05). The lumbar BMD, femoral neck BMD, (P <0.05). The lumbar BMD, femoral neck BMD and 25-hydroxyvitamin D3 in treatment group 1 after treatment were significantly higher than those in the treatment 2 group The level of osteocalcin in patients was significantly lower than that in the two groups. The level of estradiol was significantly higher than that in the two groups. The level of cholesterol was significantly lower than that in the two groups (P <0.05). Conclusions The treatment of estradiol benzoate in premature ovarian failure patients can well promote the increase of bone mineral density, reduce the incidence of osteoporosis, and will not cause serious adverse reactions.